Company Overview
Lisata Therapeutics, Inc. functions as a clinical-stage pharmaceutical entity dedicated to the discovery, development, and commercialization of novel therapies designed to treat solid tumors and other significant diseases. The company operates within the healthcare sector, specifically inside the biotechnology industry, a domain characterized by high capital requirements and the pursuit of breakthrough medical treatments. As of the latest data, the company maintains a market capitalization of $45.34M while reporting annual revenue of $170,000 and employing a workforce of 21 individuals. These financial figures indicate that the company operates on a very small scale relative to large-cap pharmaceutical peers, reflecting the typical early-stage nature of a clinical-stage firm where revenue generation is often secondary to the advancement of investigational products like certepetide.
Financial Health
The company reports a trailing twelve-month revenue of $170,000 and a net income of -$16,586,000, while EBITDA stands at -$18,063,000. The substantial gap between the nominal revenue and the significant net loss reveals a cost structure dominated by research and development expenditures rather than commercial sales, which is standard for entities in Phase 2 clinical studies. Free cash flow is recorded at -$10,854,625, indicating that the company is currently burning cash to fund its operations and clinical trials rather than generating liquidity from business activities. Gross margin is reported at 100.0%, a metric that reflects the absence of cost of goods sold for the company's current revenue streams, whereas the operating margin of -3079.0% and profit margin of 0.0% highlight severe operational inefficiencies relative to sales volume due to high fixed research costs. The company holds $15.96M in cash with no reported debt, resulting in a debt-to-equity ratio that is N/A, which suggests a conservative balance sheet free from leverage that typically burdens developing biotechnology firms. The current ratio stands at 5.76, a figure that indicates strong short-term liquidity and the ability to cover short-term obligations many times over with existing current assets. Return on Equity is -75.5% and Return on Assets is -43.2%, metrics that reveal management is currently deploying capital at a loss, a common occurrence in the early development phases where investment is required to reach marketable therapies.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the net loss, while the forward P/E is calculated at -7.61, a negative figure that implies the market expects earnings to remain negative or for the company to continue investing heavily before profitability. The price-to-book ratio is 2.98, indicating that the market values the company at nearly three times its book value, a premium often seen in biotechnology stocks where intangible assets like intellectual property and clinical data are not fully captured on the balance sheet. The price-to-sales ratio is an exceptionally high 266.72, and the EV/EBITDA is -1.61, both of which suggest that traditional valuation multiples are not applicable and that investors are pricing in future clinical success rather than current financial performance. The stock has traded between a 52-week low of $1.81 and a 52-week high of $5.07, meaning the current valuation sits within a range that reflects significant volatility typical of small-cap biotech assets. The beta is 1.27, which signifies that the stock price is more volatile than the broader market, moving 27% more aggressively in response to general market shifts.
Growth & Income
Revenue growth year-over-year is -90.0%, while earnings growth year-over-year is N/A due to the lack of prior period profitability, implying that the company is not in a growth phase regarding sales but rather in a contraction or stabilization phase prior to commercialization. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests all available cash flow back into research, development, and clinical trials rather than distributing returns to shareholders. The overall growth and income profile is characterized by negative revenue growth and zero current income generation, relying entirely on the potential future value of its investigational product certepetide to transition from a cash-burning entity to a revenue-generating business.